Form 144 Filer Information SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK0001801917Filer CCCXXXXXXXIs this a LIVE or TEST Filing?Is LIVE TESTSubmission Contact InformationIs this a Live of the second secon

Name Phone E-Mail Address

144: Issuer Information

| Name of Issuer | Roivant Sciences Ltd. |
|--|--|
| SEC File Number | 001-40782 |
| Address of Issuer | CLARENDON HOUSE, 2 CHURCH STREET HAMILTON HM11 BERMUDA HM11 |
| Phone | 441-295-5950 |
| Name of Person for Whose Account the Securities are To Be Sold | Venker Eric |
| | |

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Officer

144: Securities Information

| Title of the Class of Securities To Be Sold | Name and Address of the Broker | Number of Shares or Other Units To Be Sold | Aggregate Market Value | | | Name the Securities Exchange |
|--|--|---|---------------------------|-----------|------------|------------------------------------|
| Common | Rockefeller Financial LLC 45 Rockefeller Plaza - Floor 5 New York NY 10111 | 606221 | 6211506.90 | 771742197 | 10/03/2023 | NASDAQ |

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Amount of Title of the Date you Nature of Name of Is Date Date of Nature of Class Acquired Acquisition Person from this Donor Securities Payment Payment *

| | Transaction | Whom Acquired | a Acquire Gift? | d Acquired | |
|--------|--|--------------------------|--------------------|------------|-----------------|
| Common | Options Exercise · 10/03/2023 Grant Date 4/20/2022 | Roivant Sciences Ltd. | | 606221 | 10/03/2023 Wire |

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

| Name and Address of Seller | Title of Securities Sold | LISTE OT | mount of ecurities Sold | Gross Proceeds |
|--|--------------------------|-----------------|-------------------------------|----------------|
| Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB | common | 07/20/2023 1593 | 387 | 1802034.65 |
| Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB | Common | 07/21/2023 1819 | 998 | 2025358.44 |
| Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB | Common | 07/21/2023 2893 | 37 | 322068.81 |
| Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB | Common shares | 07/24/2023 1629 | 97 | 179104.03 |
| Eric Venker c/o Roivant Sciences Ltd. 7th Floo 50 Broadway London X0 SW1H 0DB | Common Shares | 07/24/2023 3308 | 81 | 361645.23 |
| Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB | Common shares | 07/25/2023 2834 | 44 | 307869.19 |
| Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB | common shares | 07/26/2023 2834 | 44 | 307869.19 |
| Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB | common shares | 07/27/2023 2362 | 22 | 259448.15 |
| Erik Venker c/o Roivant Sciences Ltd. 7th Floor, 50 London, X0 X0 SW1H 0D | Common | 07/31/2023 1173 | 372 | 1397752.56 |
| Erik Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway | Common Shares | 08/01/2023 6139 | 97 | 732070.41 |
| London X0 SW1H 0DB erik Venker c/o Roivant Sciences Ltd. 7th Floor | common | 08/02/2023 1639 | 97 | 194421.65 |

| 50 Broadway London X0 SW1H 0DB | | | |
|--|--------|-------------------|------------|
| erik Venker /o Roivant Sciences Ltd. 7th Floor, 50 Broadway7th Floor, 50 Broa London X0 SW1H 0DB | common | 08/03/2023 44629 | 532317.84 |
| erik Venker /o Roivant Sciences Lt 7th Floor, 50 London X0 SW1H 0DB | common | 08/14/2023 59811 | 711028.49 |
| erik Venker c/o Roivant Sciences Ltd 7th Floor, 50 Broadway London X0 SW1H 0DB | common | 08/22/2023 16105 | 174417.15 |
| erik Venker c/o Roivant Sciences Ltd 7th Floor, 50 Broadway London X0 SW1H 0DB | common | 09/01/2023 14763 | 175612.86 |
| Eric Venker c/o Roivant Sciences Ltd. 7th Floor, 50 Broadway London X0 SW1H 0DB | common | 09/05/2023 73275 | 873311.45 |
| Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB | common | 09/08/2023 5926 | 70233.61 |
| Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB | Common | 09/22/2023 16416 | 167279.04 |
| Eric Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB | common | 09/27/2023 500000 | 6510386.94 |
| Erik Venker c/o Roivant Sciences Ltd. 7th Floor 50 Broadway London X0 SW1H 0DB | common | 10/02/2023 440752 | 4759774.30 |

144: Remarks and Signature

| Remarks | The shares reported on this Form 144 will be sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 02/25/2023. |
|--|---|
| Date of Notice | 10/03/2023 |
| Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1 | 02/25/2023 |
| ATTENTION: | |

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

Jason Coleman as a duly authorized representative of National Financial Services LLC, as attorney-in-fact for Eric Venker

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)